OXS-3550

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameOXS-3550
Drug Alias NameOXS-3550-TriKEGTB-3550OXS-3550OXIS-3550161533-TriKE +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionLow affinity immunoglobulin gamma Fc region receptor III-A agonistsMyeloid cell surface antigen CD33 inhibitorsInterleukin-15 receptor subunit alpha agonists
TargetsMyeloid cell surface antigen CD33Low affinity immunoglobulin gamma Fc region receptor III-AInterleukin-15 receptor subunit alpha
Therapy Area/IndicationsMyelodysplastic SyndromesMastocytosis, SystemicLeukemia, Myeloid, Acute +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of MinnesotaOxis Biotech
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGt Biopharma Inc
Active IndicationsN/A
Inactive IndicationsMyelodysplastic SyndromesMastocytosis, SystemicLeukemia, Myeloid, Acute +[4] 

Other Information

ATC CodeN/A
Related LinksN/A